Innovation Pharmaceuticals Inc (IPIX)

[Minnesinger]

I wholeheartedly agree. I wish more people...

would understand and embrace this concept. Anecdotes may move markets (and when they do it's almost always fleeting) but they don't move the FDA. We need to impress the FDA with valid, clinically meaningful science.

I would rather the trial takes longer and produces statistically meaningful results.

The control group needs to be as close to identical to the treatment group to power the results. This takes time. Dosing 60 patients with brilacidin is not a large group and even a couple poor controls could cloud the results.